文献速递乳腺癌放疗放疗物理与技术

奥拉帕利联合放疗治疗三阴性乳腺癌:RADIOPARP I期试验初步结果

Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-09-21

RADIOPARP是一项单中心I期试验,评估奥拉帕利联合局部区域放疗在经新辅助化疗的三阴性乳腺癌患者中的剂量限制性毒性和最大耐受剂量。

要点

  • 奥拉帕利可递增至200 mg每日两次的最大目标剂量,建议未来试验采用该剂量。
  • 需进一步随访评估晚期毒性。

核心结论

  • 奥拉帕利联合局部区域放疗在三阴性乳腺癌患者中未观察到剂量限制性毒性,可递增至200 mg每日两次的最大目标剂量。

研究设计与样本

  • 放疗剂量为50 Gy至乳腺或胸壁,淋巴结是否纳入靶区依据当地指南。
  • 剂量探索采用基于时间-事件持续再评估方法的序贯自适应贝叶斯方案,奥拉帕利设4个剂量水平(50、100、150、200 mg每日两次)。

主要发现

  • 所有患者完成全疗程联合治疗:50 mg每日两次4例,100 mg每日两次8例,150 mg每日两次7例,200 mg每日两次5例。
  • 未观察到剂量限制性毒性。

关键数值与推荐

  • 奥拉帕利递增至最大目标剂量200 mg每日两次,未出现剂量限制性毒性。
  • 基于RADIOPARP长期结果待定,建议未来试验采用奥拉帕利200 mg每日两次。

临床怎么用

  • 对于经新辅助化疗的三阴性乳腺癌患者,奥拉帕利200 mg每日两次联合50 Gy局部区域放疗可作为未来试验的推荐剂量方案。
  • 需进一步随访评估晚期毒性。

局限性

  • 本文为初步结果,晚期毒性需进一步随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preclinical studies have evidenced that triple-negative breast cancer (TNBC) cell lines are more sensitive to poly (ADP-ribose) polymerase inhibitors. This provides a strong rationale for developing a new therapeutic approach for TNBC management based on poly (ADP-ribose) polymerase inhibition. The primary goal of the RADIOPARP phase 1 trial was to evaluate the dose-limiting toxicities (DLT) and the maximum tolerated dose of olaparib combined with locoregional radiation therapy. METHODS AND MATERIALS: RADIOPARP was a single institutional phase 1 trial which evaluated olaparib-radiation therapy combination in patients with inflammatory, locoregionally advanced or metastatic TNBC who received neoadjuvant chemotherapy. Radiation therapy delivered 50 Gy to the breast or to the chest wall. Lymph nodes could be included in target volumes according to local guidelines. The dose-finding toxicity-based study was conducted in sequential and adaptive Bayesian scheme using the time-to-event continual reassessment method, with 4 olaparib dose levels (50 mg, 100 mg, 150 mg, and 200 mg twice per day). RESULTS: Twenty-four patients with Eastern Cooperative Oncology Group Performance Status of 0 or 1 were enrolled from September 2017 to November 2019. Twenty-one patients (87.5%) received the olaparib-radiation therapy combination after breast surgery owing to residual disease after neoadjuvant chemotherapy, and the 3 other patients (12.5%) had unresectable tumors which were refractory to neoadjuvant chemotherapy. All patients received full course combination treatment as follows: 4 patients (pts) at 50 mg twice a day, 8 pts at 100 mg twice a day, 7 pts at 150 mg twice a day, and 5 pts at 200 mg twice a day. No DLT was observed. CONCLUSIONS: Olaparib was escalated to the maximum target dose of 200 mg twice a day without DLT. Further follow-up is needed to evaluate the late toxicities. Pending the long-term results of the RADIOPARP trial, we suggest using 200 mg of olaparib twice per day for future trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Loap P, Loirat D, Berger F, et al. Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32971187. doi:10.1016/j.ijrobp.2020.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。